肝内肿块型胆管癌切除标本肿瘤-间质比的前瞻性研究:预后价值及与钆塞酸二钠增强MRI的相关性
前瞻性纳入86例疑似肝内肿块型胆管癌并接受钆塞酸二钠增强MRI及根治性切除的患者,分为间质贫乏组(32例)与间质丰富组(54例)。间质贫乏组复发风险更高,肿瘤-间质比是全队列及小胆管亚型无复发生存期的独立预测因子;肝胆期对比增强率与肿瘤-间质比相关。
要点
- 间质贫乏型肝内肿块型胆管癌复发风险高于间质丰富型,全队列p=0.002。
- 肿瘤-间质比是全队列无复发生存期的独立预测因子(HR=2.755)。
- 肝胆期对比增强率与肿瘤-间质比相关,或可用于无创评估间质贫乏。
核心结论
- 间质贫乏与肝内肿块型胆管癌的不良预后相关,尤其在小胆管亚型中。
- 肝胆期对比增强率是肿瘤-间质比无创评估的有前景工具。
研究设计与样本
- 前瞻性研究,纳入2022年3月至2024年12月疑似肝内肿块型胆管癌并接受钆塞酸二钠增强MRI及根治性切除的参与者86例(平均年龄65±9岁)。
- 共86例中,小胆管型60例、大胆管型26例;间质丰富组54例、间质贫乏组32例。
- 采用Cox回归分析和Kaplan-Meier曲线比较无复发生存率,采用Logistic回归分析识别与肿瘤-间质比相关的因素。
诊断标准与关键数值
- 间质贫乏型肝内肿块型胆管癌在全队列(p=0.002)和小胆管亚型(p<0.001)中复发风险均高于间质丰富型。
- 肿瘤-间质比预测全队列无复发生存期的风险比为2.755(95%CI:1.324,5.735;p=0.007)。
- 肿瘤-间质比预测小胆管亚型无复发生存期的风险比为4.053(95%CI:1.575,10.431;p=0.004)。
- 肝胆期对比增强率与全队列肿瘤-间质比相关(比值比=0.016;95%CI:0.001,0.259;p=0.004)。
- 肝胆期对比增强率与小胆管亚型肿瘤-间质比相关(比值比=0.020;95%CI:0.001,0.544;p=0.020)。
临床应用与阅片要点
- 肝胆期对比增强率可用于无创评估肝内肿块型胆管癌的肿瘤-间质比,尤其在小胆管亚型中。
- 肿瘤-间质比可作为预后指标,可能有助于制定新的个体化治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the prognostic value of tumor-stroma ratio (TSR) in intrahepatic mass-forming cholangiocarcinoma (IMCC) and its subtypes, and to explore the correlation between gadoxetic acid-enhanced MRI and TSR.
MATERIALS AND METHODS: This prospective study included participants with suspected IMCC who underwent gadoxetic acid-enhanced MRI and curative resection between March 2022 and December 2024. Participants were divided into stroma-poor and stroma-rich groups. Clinicopathologic and MRI features were assessed. Cox regression analysis and Kaplan-Meier curves were used to compare recurrence-free survival (RFS) rate. Logistic regression analysis was used to identify factors associated with TSR.
RESULTS: A total of 86 participants (mean age 65 ± 9 years) were included, with 60 small-duct (SD) and 26 large-duct (LD) IMCC; 54 were classified as stroma-rich and 32 as stroma-poor. Participants with stroma-poor IMCC had a higher risk of recurrence than those with stroma-rich IMCC in the whole cohort (p = 0.002) and in the SD subtype (p < 0.001). TSR was an independent predictor for RFS in the whole cohort (hazard ratio = 2.755; 95% CI: 1.324, 5.735; p = 0.007) and in SD subtype (hazard ratio = 4.053; 95% CI: 1.575, 10.431; p = 0.004). The contrast-enhancement ratio on hepatobiliary phase (CERHBP) image was associated with TSR in the whole cohort (odds ratio = 0.016; 95% CI: 0.001, 0.259; p = 0.004) and in SD subtype (odds ratio = 0.020; 95% CI: 0.001, 0.544; p = 0.020).
CONCLUSION: Poor tumor-stroma is associated with an unfavorable prognosis in IMCC, especially in the SD subtype. The CERHBP is a promising tool for the noninvasive assessment of TSR.
KEY POINTS: Question The prognostic implication of the TSR in IMCC and its subtypes, and its correlation with gadoxetic acid-enhanced MRI characteristics, remain inadequately understood. Findings Poor tumor-stroma is identified as a significant risk factor for recurrence, and the CERHBP is associated with TSR in SD IMCC. Clinical relevance This study introduces a noninvasive approach to evaluate TSR in IMCC, especially in the SD subtype, and underscores the significance of TSR as a prognostic indicator, potentially aiding in the development of new personalized therapeutic strategies.
引用
- Pan YJ, Chen LL, Wang Z, et al. A prospective study of tumor-stroma ratio in resected intrahepatic mass-forming cholangiocarcinoma: prognostic value and correlation with gadoxetic acid-enhanced MRI. Eur Radiol. 2025. PMID: 41307660. doi:10.1007/s00330-025-12169-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。